Salt Lake City, UT, Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- NutraNomics is excited to introduce the principals behind our partnership with Tempus Bio Technologies. Tracy Holford, Ph.D. and Dr. J. Frederick Templeman are our exceptionally well qualified, strategic partners in the science community. The doctors represent our continued drive toward our goal of bringing cutting-edge technology and delivery systems to our company formulations, furthering the efficacy and specific biological targeting of our product lines in vivo.
Tracy Holford Ph.D. - Chief Scientist and Formulator, Tempus Bio Technologies
Dr. Holford holds advanced degrees in Microbiology, Inorganic Chemistry, Biochemistry, Environmental Chemistry, including Ph.D.'s in Inorganic Chemistry, Biochemistry, and Nuclear Physics. Since 1991 he has had a private practice consulting on medical and nutritional aspects of illness in conjunction with the medical community. In 2009, Dr. Holford joined Mentis Consulting for projects involving nutritional programs, specifically incorporating advanced technologies involving physics and biochemistry. Other engagements have included working with the Department of Defense, holding CEU workshops and classes for the St. John's Regional Health Center, participating in the (Missouri) Governor's Council on Health Care, several science board memberships and speaking engagements the latest being the Autism One Conference (2015).
Dr. J. Fredric Templeman – Lead Medical Consultant, NutraNomics, Inc.
Dr. Templeman is a Canadian-trained family doctor who, during his years as a clinician, was board certified in both Canada and the US where he practiced. He practiced actively from 1984 until 2009. He retains his active license as a physician in his capacity as a medical director of a medical spa but sees no private patients at present. In addition to the standard duties of a family physician, Dr. Templeman has special training in medical hypnotherapy, family therapy and the treatment of mood disorders, in addition to being an expert on the benefits of mangosteen.
Dr. Templeman has consulted widely with companies involved in the medical supplement industry over the past 15 years. During this time, he has been actively involved in adverse event reporting, product evaluation, product formulation and the application of nanobiotechnology in supplementation.
Reformulation of NutraNomics Products
In May of 2019, NutraNomics embarked on the arduous task of reformulation to bring the existing product line up to standard with the newest and most effective delivery system, moving from a digestive delivery to a pre-digestive delivery using Nano Technology. With over 280+ plant-based formulations, there is plenty of work to do. Amazon Factor has been identified as the first product for reformulation for numerous reasons, the primary two being customer demand and overall complexity of the end product and its ingredients. Amazon Factor will also undergo a complete renaming and rebranding strategy in the launch of the new formula.
Nano Technology is not new, being established in 1858, but it is making a resurgence in the nutraceutical industry. Dr. Holford is a leading formulator who has studied and understands not only the intricate workings required to effectively nano-size botanicals for maximum bioavailability, but has a comprehensive knowledge of how to successfully navigate labeling and marketing with the FDA rules and guidelines.
In the conventional metabolization of a traditional, pill-based formulation, 4-5% of the active ingredient is absorbed in each serving. Some high-quality supplements can reach as high as 20% utilization of the botanical. Nanotechnology can prove absorption up to 95% by reducing the size of the particle. Utilizing blood tests following a standardized testing protocol, it is easy to prove efficacy.
“If you want the best for your patients, customers, and yourself, you want the whole cake, not the crumbs. With traditional digestive delivery method, you get only crumbs,” says Dr. Tracy Holford. “Maintaining the integrity of the botanical is critical. With today’s technology, we can not only nano-size, we can prove the efficacy at a significantly reduced volume of product.”
The decision tree for the nano sizing and encapsulation process relies heavily on the botanical ingredients and the purpose of those ingredients. “Practically speaking, the quantity of material used is fractional as compared to traditional delivery methods. Vitamin D3 is one of the harder elements to assimilate,” according to Dr. Fredric Templeman. “A preparation for Vitamin D3 could run $280 per gram. That same gram utilizing nano sizing could turn into 600 servings with clinical effectiveness unheard of traditional digestive delivery.”
Nano sizing is highly economical, providing better product delivery with a significantly reduced amount of product per serving, reducing overall costs and providing customers with more product for less money. Newly released FDA rules say supplement companies have to prove what is in their products by standard methods, which will dictate what can be said about the supplement in marketing to the public. Claims of nano-sizing must be supported. NutraNomics and Tempus can do this and show that there are no incipients (added ingredients) or fillers in the product and support the claims of superior bioavailability.
NutraNomics continues to work diligently to surround the organization with the very best talent in innovation, delivery and formulation practices. Expect to see three new products on the market in early 2020 featuring nano-sized delivery and a whole new look and feel in the brand. Initial product release will include a reformulated and renamed Amazon Factor featuring nano-sized powerhouse ingredients mangosteen and graviola, our nano Vitamin D3 product, and a nano mangosteen and CBD product that combines two of the most studied anti-inflammatory botanicals.
SAFE HARBOR STATEMENT
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.